Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

162.30 +2.62 (+1.64%)
Official Closing Price Updated: 7:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
3 Dividend Stocks For A Steady Drip Of Income
Dividend Reinvestment Plans allow investors to unleash the power of compounding dividends. 
Via Talk Markets
7 Must-Have Stocks for Serious Wealth Accumulation
Unlock the strategies of seven finance and commerce stalwarts on the path to serious wealth accumulation and industry leadership. 
Via InvestorPlace
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
A Closer Look at Johnson & Johnson's Options Market Dynamics
Via Benzinga
Is Johnson & Johnson Stock a Buy Now?
The pharmaceutical giant recently announced another acquisition. 
Via The Motley Fool
Balancing Dividends and Fundamentals: The Case of NYSE:JNJ.
Why JOHNSON & JOHNSON (NYSE:JNJ) provides a good dividend, while having solid fundamentals. 
Via Chartmill
The 3 Most Undervalued Value Stocks to Buy in January
With so many investments turning in a surprisingly robust performance last year, it’s time to consider undervalued value stocks. 
Via InvestorPlace
4 Fantastic Dividend King Stocks to Buy in 2024
All four of these companies have been increasing their dividend payouts for over 50 years. 
Via The Motley Fool
Hidden High-Yielders: 7 Overlooked Stocks with Attractive Dividends
Here are seven overlooked high-yield dividend stocks for you to consider no matter where interest rates at the end of 2024. 
Via InvestorPlace
2 Former Warren Buffett Stocks That Stand Out as Stong Buys in 2024
Berkshire Hathaway exited its positions in these two blue chip dividend stocks last year, but they are still superb buys for certain types of investors. 
Via The Motley Fool
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will... 
Via Talk Markets
This Dividend Stock Has a $13 Billion Secret Weapon
Johnson & Johnson made a key decision last year. 
Via The Motley Fool
2 Average Stocks That Could Make You Rich
You don't always have to pick a game-changing company to win in the stock market. 
Via The Motley Fool
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. 
Via Investor's Business Daily
Topics ETFs
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. 
Via Investor's Business Daily
Dividend Dynasty: 7 High-Yield Stocks for Long-Term Wealth Accumulation
Navigate 'Dividend Dynasty': Uncover seven high-yield stocks combining stable dividends with sustainable growth strategies. 
Via InvestorPlace
Walgreens Cut Its Dividend by 48%: Here Are 5 Better Dow Dividend Stocks to Buy in January
Businesses with efficient operations and growth potential open the door to dividend raises for years to come. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Why Eli Lilly Stock Skyrocketed 59% in 2023
Lilly's pipeline success in 2023 allowed it to to claim the crown as the biggest drugmaker on the planet by market cap. 
Via The Motley Fool
2 Dow Stocks to Buy Hand Over Fist in 2024 and 1 to Avoid Like the Plague
Among the Dow Jones Industrial Average's 30 time-tested components, there are two that are historically cheap and ripe for the picking, while another outperformer is riddled with issues. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Unshakeable Dividend Stocks for Lifelong Wealth
No matter what the circumstances, passive income won’t go out of style, thus driving the case for these long-term dividend stocks. 
Via InvestorPlace
7 Stable Stocks to Buy No Matter What Happens to Interest Rates
With investors still facing uncertainty in 2024, they may find greater comfort by targeting certain stable stocks to buy. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Illumina Shares Trading Higher After Confirming Partnership With Johnson & Johnson Unit
Illumina, Inc. (NASDAQ: ILMN) shares are trading higher after announcing preliminary financial results for the fourth quarter (Q4) and  
Via Benzinga
Want to Win in the Stock Market? Be Average.
Start with companies that have proven themselves. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
With Johnson & Johnson buying out Ambrx Biopharma, the win-win deal boosted AMAM stock while better positioning J&J’s oncology unit. 
Via InvestorPlace
J&J's Tentative $700M Agreement To Resolve Talc Powder-Related Lawsuits Across US States
Healthcare giant Johnson & Johnson (NYSE: JNJ) has reached a tentative agreement to pay approximately $700 million to settle an investigation  
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.